A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status-Reference-Cited by-同舟云学术

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Published:2017-07-18 Issue:8 Volume:6 Page:1904-1914
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Izar Benjamin¹²³^ORCID,Sharfman William⁴,Hodi F. Stephen⁵,Lawrence Donald⁶,Flaherty Keith T.⁶⁷,Amaravadi Ravi⁷,Kim Kevin B.⁸,Puzanov Igor⁹,Sosman Jeffrey⁹,Dummer Reinhard¹⁰,Goldinger Simone M.¹⁰,Lam Lyhping¹¹,Kakar Shefali¹²,Tang Zhongwen¹²,Krieter Oliver¹³,McDermott David F.¹,Atkins Michael B.¹¹⁴

Affiliation:

1. Beth Israel Deaconess Medical Center; Boston Massachusetts

2. Center for Cancer Precision Medicine/Dana-Farber Cancer Institute and the Broad Institute; Boston Massachusetts

3. Broad Institute of MIT and Harvard; Cambridge Massachusetts

4. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Baltimore Maryland

5. Dana Farber Cancer Institute; Boston Massachusetts

6. Massachusetts General Hospital; Boston Massachusetts

7. Abramson Cancer Center of the University of Pennsylvania; Philadelphia Pennsylvania

8. California Pacific Medical Center Research Institute; San Francisco California

9. Vanderbilt-Ingram Cancer Center; Vanderbilt Tennessee

10. University Hospital; Zurich Switzerland

11. Novartis Institutes for BioMedical Research; Inc.; Cambridge Massachusetts

12. Novartis Pharmaceuticals Corporation; East Hanover New Jersey

13. Novartis Pharma AG; Basel Switzerland

14. Georgetown-Lombardi Comprehensive Cancer Center; Washington District of Columbia

Funder

Novartis

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference38 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J. Clin.,2016

2. Cancer statistics, 2006;Jemal;CA Cancer J. Clin.,2006

3. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma;Middleton;J. Clin. Oncol.,2000

4. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J. Clin. Oncol.,1999

5. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

3. Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care;The Cancer Journal;2024-03

4. New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAF^V600E/VEGFR-2 inhibition, and computational studies;RSC Advances;2024

5. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities;Molecular Cancer;2023-12-18